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http://www.biomedcentral.com/1471-2407/13/96RESEARCH ARTICLE Open AccessBcl-2 associated athanogene 5 (Bag5) is
overexpressed in prostate cancer and inhibits
ER-stress induced apoptosis
Anja Bruchmann1, Corinna Roller1, Tamara Vanessa Walther1, Georg Schäfer2, Sara Lehmusvaara3, Tapio Visakorpi3,
Helmut Klocker2, Andrew C B Cato1 and Danilo Maddalo1*Abstract
Background: The Bag (Bcl-2 associated athanogene) family of proteins consists of 6 members sharing a common,
single-copied Bag domain through which they interact with the molecular chaperone Hsp70. Bag5 represents an
exception in the Bag family since it consists of 5 Bag domains covering the whole protein. Bag proteins like Bag1 and
Bag3 have been implicated in tumor growth and survival but it is not known whether Bag5 also exhibits this function.
Methods: Bag5 mRNA and protein expression levels were investigated in prostate cancer patient samples using real-
time PCR and immunoblot analyses. In addition immunohistological studies were carried out to determine the
expression of Bag5 in tissue arrays. Analysis of Bag5 gene expression was carried out using one-way ANOVA and
Bonferroni’s Multiple Comparison test. The mean values of the Bag5 stained cells in the tissue array was analyzed by
Mann-Whitney test. Functional studies of the role of Bag5 in prostate cancer cell lines was performed using
overexpression and RNA interference analyses.
Results: Our results show that Bag5 is overexpressed in malignant prostate tissue compared to benign samples. In
addition we could show that Bag5 levels are increased following endoplasmic reticulum (ER)-stress induction, and Bag5
relocates from the cytoplasm to the ER during this process. We also demonstrate that Bag5 interacts with the ER-
resident chaperone GRP78/BiP and enhances its ATPase activity. Bag5 overexpression in 22Rv.1 prostate cancer cells
inhibited ER-stress induced apoptosis in the unfolded protein response by suppressing PERK-eIF2-ATF4 activity while
enhancing the IRE1-Xbp1 axis of this pathway. Cells expressing high levels of Bag5 showed reduced sensitivity to
apoptosis induced by different agents while Bag5 downregulation resulted in increased stress-induced cell death.
Conclusions: We have therefore shown that Bag5 is overexpressed in prostate cancer and plays a role in ER-stress
induced apoptosis. Furthermore we have identified GRP78/BiP as a novel interaction partner of Bag5.
Keywords: Unfolded protein response, Cell stress, Endoplasmic reticulum, Apoptosis, Molecular chaperones, RefoldingBackground
The Bag (Bcl-2 associated athanogene) protein family
consists of 6 evolutionary conserved polypeptides (Bag1-
Bag6) [1]. They share a common, C-terminal, single-
copied BAG domain consisting of three alpha helices
that interact with and modulate the activity of the
molecular chaperone Hsp70 [2]. Structural biology and* Correspondence: danilo.maddalo@kit.edu
1Karlsruhe Institute of Technology, Institute of Toxicology and Genetics,
Hermann-von-Helmholtz Platz 1, Eggenstein-Leopoldshafen 76344, Germany
Full list of author information is available at the end of the article
© 2013 Bruchmann et al.; licensee BioMed Ce
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumlimited proteolysis studies identified the Bag domain as
a 110-124 amino acid motif consisting of three antiparal-
lel alpha helices of 30-40 amino acids each [2-4]. How-
ever the length of the Bag domain varies among the
Bag family members, producing two distinct sub-
groups: a ‘long’ Bag domain present in Bag-1 family of
proteins and a ‘short’ Bag domain of Bag-3, Bag-4 and
Bag-5 [5].
Several of the Bag proteins have been implicated in
the control of apoptosis [6,7]. Bag-1 and Bag-3 (Bis)
interact with Bcl-2 to reduce apoptosis induced by sev-
eral factors [6,8]. Bag-4 (Sodd) associates with andntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Bruchmann et al. BMC Cancer 2013, 13:96 Page 2 of 11
http://www.biomedcentral.com/1471-2407/13/96blocks signaling of receptors of the tumor necrosis fac-
tor family [9,10]. Bag-6 (Scythe) modulates the nuclear
pathway that communicates with mitochondria and
regulates the release of cytochrome c thereby controlling
apoptosis [11,12].
Other than the common Bag domain, Bag proteins do
not share any homology in terms of sequence and encode
for distinct domains: Bag-3 contains at its N-terminal re-
gion a WW domain [13] and a PXXP domain [14] while a
ubiquitin-like domain is present in the central part of the
Bag-1 proteins and in a double copy at the N-terminal
part of Bag-6 [15]. Bag5 is exceptional in this group of
polypeptides since it consists solely of 5 BAG domains
structured in two and a half helices [5].
Bag proteins enhance cell proliferation and survival
[16,17] and increase stress tolerance and therefore con-
tribute to cancer development [18-20]. However the only
function of Bag5 known so far is the inhibition of the ac-
tivity of Hsp70 and the E3 ubiquitin ligase Parkin [21,22]
in Parkinson’s disease. A possibility exists that like the
other Bag proteins it may also be involved in tumor pro-
gression although this has not been demonstrated.
In this communication we show that Bag5 is
overexpressed in prostate cancer and exerts an anti-
apoptotic function. We further demonstrate that Bag5 is
a stress inducible gene that functions as a co-chaperone
of GRP78/BiP and that its increased expression results
in increased resistance to UPR-induced apoptosis.
Methods
Antibodies
Rabbit polyclonal anti-eIF2α FL315, goat monoclonal
anti-GRP78 (N20), mouse monoclonal anti-Bag5 (18Z)
and anti-tubulin (TU-02) antibodies were purchased
from Santa Cruz Biotechnology (Heidelberg, Germany).
Rabbit polyclonal anti-GRP78 (ab21685) and anti-Bag5
(ab97660) antibodies were purchased from Abcam
(Cambridge, UK). Rabbit polyclonal anti-GRP78 (ET21)
and anti-β-actin antibodies were purchased from Sigma
(Steinheim, Germany). Mouse antibody against HA (HA.11
clone 16B12) was purchased from Covance (Munich,
Germany). Antibodies against PARP, ATF4, IRE1α, CHOP,
phospho-IRE1α, phospho-eIF2α and PERK were pur-
chased from Cell Signaling Technology (Frankfurt am
Main, Germany). Anti-ATF6 antibody was purchased from
Imgenex (Hamburg, Germany).
Cell culture
All cell lines used in this work were purchased from
ATCC.
22Rv.1, LNCaP and PC3 cells were cultivated in RPMI
1640 medium supplemented with 10% fetal calf serum
(FCS). HEK293 cells were cultivated in Dulbecco´ s modi-
fied Eagle´ s medium (DMEM) supplemented with 10%FCS. RWPE-1, WPE-NB14 and WPE-NB26 cells were
cultivated in keratinocyte serum free medium. All the
cell culture media were purchased from Invitrogen
(Karlsruhe, Germany).
Cell treatments
Unless otherwise stated, cells were treated for the in-
dicated time points with a final concentration of 300 nM
thapsigargin (Life Technology, Hamburg, Germany), 10
μg/ml tunicamycin (Sigma, Steinheim, Germany), 20 μM
fenretinide (Enzo Life Sciences, Lörrach, Germany), 10 μM
(-)-epigallocatechingallate (EGCG, Santa Cruz, Heidelberg,
Germany) and 10 nM Taxol (Sigma, Steinheim, Germany).
Glucose starvation was performed cultivating the cells in
glucose-free medium supplemented with 10% dialyzed
FCS. Serum starvation was performed cultivating the cells
in serum-free medium.
Transfection experiments and siRNA
22Rv.1 and PC3 stably transfected with empty vector or
Bag5 with FuGene6W (Promega, Mannheim, Germany).
For the generation of stable pooled clones, cells were
cultivated in RPMI supplemented with 10% FCS and
0.8 mg/ml G418 final concentration. HEK293 cells were
transiently transfected with PromoFectinW (PromoKine,
Heidelberg, Germany) according to the manufacturer’s
recommendations. For siRNA experiment, cells were
transfected with HiperFect (Qiagen, Hilden, Germany)
with RNA antisense targeted against Bag5 or GFP as
control. siRNA was purchased from Life Technologies
(Darmstadt, Germany).
Immunofluorescence
Immunofluorescence experiments were carried out on
cells seeded in a 2-well glass slide (Lab-TekW Chamber
Slide System). After treatment with vehicle (ethanol
80%) or 300 nM thapsigargin, the medium was removed
and the cells were stained with anti-Bag5 antibody and
anti-PDI antibody (to track the ER). Samples were
analyzed with a Leica TCS SPE confocal microscope. An
IMARIS ColocW (Bitplane, Zurich, Switzerland) module
was used to calculate the co-localized voxels (volume
unit, analogous to a pixel in two dimension images) be-
tween the two channels.
Quantification of protein extracts
Protein concentration was quantified with the Bio-Rad
Protein Assay (Bio-Rad, Munich, Germany) according to
manufacturer’s instructions.
Protein extraction
For protein extraction, cells were washed once with PBS
1X and resuspended in lysis buffer (50 mM Tris pH 8.0,
150 mM NaCl, 5 mM EDTA, 1% NP-40, 0.1% SDS,
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rial, 8 μm-thick frozen tissue sections were homogenized
in lysis buffer with the TissueLyser (Qiagen, Hilden,
Germany) and frozen at -80°C. Samples were centrifuged
at 12000 × g for 10 min at 4°C, quantified, resuspended in
sample buffer and boiled at 95°C for 5 minutes.
Endoplamsic reticulum fractionation
Endoplasmic Reticulum fractionation was performed with
the ER enrichment kit from Imgenex (Hamburg, Germany).
After thapsigargin treatment cells were washed with PBS
1X by centrifugation at 2000 × g for 5 min. For homog-
enization, the cell pellet was resuspended in 1.5 ml of 1X
isosmotic homogenization buffer supplemented with prote-
ase inhibitor cocktail and transferred into a glass tubes
for the homogenizer (Braun, Melsungen, Germany). The
samples were homogenized with the TissueLyser (Qiagen,
Hilden, Germany). The homogenate was transferred into a
new tube and centrifuged for 10 minutes at 1000 × g at 4°C
to eliminate nuclei and cell debris. The supernatant was
transferred into a new tube and centrifuged for 15 minutes
at 12000 × g at 4°C to eliminate the mitochondria and the
cell debris. The resulting supernatant was ultracentrifuged
1 h at 90000 × g for 1 h at 4°C. The pellet containing the
ER was resuspended in 1X suspension buffer supplemented
with protease inhibitor cocktail and dissolved by pipetting
and vigorous vortexing.
mRNA extraction and real time PCR
Total RNA was extracted with PeqGold (PeqLab, Erlangen,
Germany) and first-strand cDNA synthesis was performed
using the M-MLV reverse transcriptase (Promega, Mannehim,
Germany) and random primers (Fermentas, St Leon-Rot,
Germany). For q-RT-PCR analysis the Maxima SYBR Green/
Rox qPCR Master Mix (Fermentas, St-Leon-Rot, Germany)
and StepOne Plus Real-Time System apparatus (Applied
Biosystems, Darmstadt, Germany) were used.
For Real Time PCR analysis the following primers
were used: Bcl2, forward 50-ATGTGTGTGGAGAGCGT
CAACC-30, reverse 50-TGAGCAGAGTCTTCAGAGA
CAGCC-30; Bax, forward 50- CCTTTTCTACTTTGCCA
GCAAAC-30, reverse 50- GAGGCCGTCCCAACCAC-30;
CHOP, forward 50-TGGTCATTCCCCAGCCCGGG-30, re-
verse 50-TTCCCTGGTCAGGCGCTCGA-30; Xbp1 spliced
(Xbp1s) forward 50-CCGGTCTGCTGAGTCCGCAGC-30,
reverse 50-TGGCAGGCTCTGGGGAAGGG-30; Bag5 for-
ward 50-TGTCCCCGGGTTTAGGGGTGTTC-30, reverse
50-TTCACAAGCACTGTCCCGCCC-30; GRP78/BiP for-
ward 50-CGACCTGGGGACCACCTACT-30, reverse 50-TT
GGAGGTGAGCTGGTTCTT-30. Gene expression data
analysis was normalized against the Ribosomal Protein 36
(Rib36). For Rib36 the forward 50-GAAGGCTGTGGTG
CTGATGG-30 and reverse 50-CCGGATATGAGGCAGCA
GTT-30 primers were used.For Bag5 gene expression level in patient material, a
set of 42 samples was used, including 15 benign pros-
tatic hyperplasia (BPH) and 27 prostate cancer samples
obtained from radical prostatectomy. The set of samples
was obtained from the Tampere University Hospital
(Tampere, Finland). The specimens were confirmed to
contain >70% of malignant or non-malignant epithelial
cells using hematoxylin and eosin-stained slides. Total
RNA was extracted from the frozen sections with Trizol
(Invitrogen, Hämeenlinna, Finland), and first-strand
cDNA synthesis was performed using SuperScript III re-
verse transcriptase (Invitrogen, Hämeenlinna, Finland)
and random primers (Fermentas, Glen Burnie, MA).
Bag5 gene expression was analyzed with the following
primers: forward 50-AGGTGTCCCCGGGTTTAG-30 and
reverse 50-GATGTTGGTTTCCCATATCCA-30. Values
were normalized to β-actin using the primers: forward
50-TGGGACGACATGGAGAAAAT-30 and reverse 50-
AGAGGCGTACAGGGATAGCA-30. For q-RT-PCR ana-
lysis the Maxima SYBR Green/Rox qPCR Master Mix
(Fermentas, Helsinki, Finland) and CFX96 Real-Time Sys-
tem apparatus (Bio-Rad, Helsinki, Finland) were used.
Statistical analysis
Unless otherwise stated, calculations of statistical signifi-
cance in this work were performed according to Student’s
t test. For comparison of the mean values in Bag5 gene
expression study in BPH and Prostate Cancer patients
one-way ANOVA and Bonferroni’s Multiple Comparison
test were used. For comparison of the mean values of
Bag5 stained cells in the tissue array analysis the Mann-
Whitney test was used.
Protein extraction from prostate tissue and tissue array
Radical prostatectomy specimens were obtained from
patients undergoing surgery after prostate cancer diag-
nosis in the Tyrolean PSA Screening project for early
detection of prostate cancer [23,24] and were worked up
according to the standard histopathology protocol. The
use of archive tumor tissue samples was approved by the
Ethics Committee of the Innsbruck Medical University.
A tissue microarray containing tissue cores of 91 can-
cer cases was prepared as described in [25] and double
stained with a polyclonal rabbit Bag5 antiboby (Imgenex,
Hamburg, Germany) diluted 1:500 in Ventana diluent
and a monoclonal antibody directed against the basal
cell marker p63 (Clone 4A4 + Y4A3, Neomarkers, MS
Cat 1084-P0) diluted 1:100 in Ventana diluent using a
Ventany Discovery-XT staining automate (Ventana, Roche,
Mannheim, Germany). Immunoreactivity was scored by an
uropathologist (G.S.) considering the number of positive
cells and the intensity of immunostaining for Bag5. Each
case included 3 cores of tumor and 1 core of benign tissue.
According to the percentage of positive cells a score
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1 = 10-25%; 2 = 25-50%; 3 = 50-75%; 4 = 75-100%). For
each case, the value assigned to the tumor is the aver-
age of the three tumor cores. Immunostaining for the
basal cell marker p63 present only in benign tissue
served as a control for accurately distinguishing be-
nign and tumor tissue.Colorimetric assay of ATP hydrolysis
ATP hydrolysis was measured using an ATPase assay kit
from Innova Biosciences (Cambridge, UK). Briefly, 0.5 μg
of purified GRP78 (StressMarq Biosciences, Victoria,
Canada) was incubated in a buffer consisting of 0.5 M Tris
pH 7.5 and 1 mM ATP in presence or absence of 0.17 μg
of GST-Bag5 or GST-BagΔ 5 at 37°C. The experiment
performed in presence only of GST-Bag5 was set as back-
ground control. After 30, 45 and 60 min, 50 μl
PiColorLock™ Gold reagent and Accelerator were added
to the solution. 2 minutes later 20 μl of stabilizer were
added and the resulting green color was allowed to de-
velop for 30 minutes at room temperature. Absorbance
was measured at 595 nm. Enzymatic activity was cal-
culated according to manufacturer’s instructions.Co-immunoprecipitation
For in vivo protein-protein interaction studies, co-
immunoprecipitation experiment was performed by
continuous rotation of protein A sepharose beads in TE
buffer (10 mM Tris pH8 and 0,1 mM EDTA pH 8) with
4 μg of anti-GRP78/BiP specific antibody for 2 h at
4°C. HEK293 cells were treated with 2 nM Dithiobis
(succinimidyl propionate) (DSP) in 10 ml PBS 1X for 30 -
minutes at room temperature (RT) to crosslink endoge-
nous proteins. Crosslinking was stopped by the addition
of 20 mM Tris pH7.5 for 15 minutes at RT. Thereafter
cells were centrifuged at 2000 rpm for 5 minutes and the
pellet lysed in 1 ml lysis buffer (50 mM Tris pH7,4,
120 mM NaCl, 1 mM EDTA, 0.4% NP-40). Cell lysate
was sheered by passage 10 times through a 23 G needle
(Braun, Melsungen, Germany), sonified (Amp 60, 10
pulses) and centrifuged for 10 minutes at 12000 × g at 4°C.
The cell lysate and the beads were then incubated over
night at 4°C boiled at 95°C and finally subjected to SDS-
PAGE and western blot analysis.Caspase 3 cleavage measurement
Caspase 3 cleavage was measured with the CaspACE™
Assay System (Promega, Mannheim, Germany). 1·104
cells were seeded in a 96 well plate and treated for 24 -
hours as indicated in the figure legend. At the end of the
treatment, cells were lysed and Caspase 3 activity was
measured according to manufacturer’s instructions.Results
Bag5 is overexpressed in prostate cancer
To determine whether Bag5 plays a role in prostate can-
cer development, we first analyzed its expression in be-
nign prostatic hyperplasia (BPH) and compared it with
its expression in prostate cancer. We observed at the
RNA level that only 13% of the BPH samples (2/15)
expressed Bag5 compared to 59% tumor probes (16/27)
(Figure 1A). In addition immunohistochemical analysis
of Bag5 was performed on a tissue microarray con-
taining benign and malignant prostate tissues from a
core of 91 cancer cases (Figure 1B). Staining score of the
percentage of cells positive for Bag5 was significantly
increased in the malignant compared to the benign
tissues (Figure 1C). Furthermore, analysis of Bag5 ex-
pression was performed in an immunoblot assay on
Gleason 9 prostate cancers and their corresponding be-
nign surrounding area. In this study, no Bag5 expression
was detected in the benign biopsies while 3 out of the
4 cancer samples analyzed (75%) were positive for Bag5
(Figure 1D). These results demonstrate that Bag5 ex-
pression is increased in prostate cancer both at the RNA
and protein level.
The tumor-specific expression of Bag5 was not restricted
to biopsies but could be reproduced in a cell culture model
of prostate cancer progression where RWPE-1, WPE-
NB14 and WPE-NB26 represent different stages of malig-
nancy from benign to a more aggressive prostate tumor
state (reviewed in [26]). Here again, increased Bag5 expres-
sion was found in the tumor compared to the benign cell
lines (Figure 1E). In addition we could show in established
prostate cell lines that Bag5 expression is high in the more
aggressive PC3 cells compared to less aggressive 22Rv.1
and LNCaP cells and the benign-prostatic hyperplasia
(BPH-1) derived cells (Figure 1F).
ER stress enhances Bag5 expression and alters its
cytoplasmic localization
Previous reports have implicated the Bag proteins in the
development of stress tolerance [19,27], one of the key
features for cancer growth and chemoresistance. We
therefore investigated whether Bag5 expression levels
are influenced by stress. Treatment of 22Rv.1 cells with
the stress inducers thapsigargin (TG) or tunicamycin
(TN) up to 12 h resulted in a significant increase in
Bag5 mRNA expression (Figure 2A). The increased ex-
pression of Bag5 following TG and TN treatment oc-
curred concomitantly with an increased expression of
the ER-chaperone GRP78/BiP (Figures 2B). Bag5 and
GRP78/BiP protein levels were also increased following
treatment of the 22Rv.1 cells with TG and TN (Figure 2C).
Similar results were obtained in the metastatic cell line
PC3 that as previously shown in Figure 1F expresses high
levels of Bag5 (Additional file 1: Figure S1).
Figure 1 Bag5 is overexpressed in prostate cancer. Bag5 expression analysis in prostate cancer tissue and cell lines. A. Quantitative RT-PCR
studies showing the relative expression of Bag5 in benign prostate hyperplasia (BPH, n = 15) and prostate cancer (PCa, n = 27). The expression
values were normalized against the expression of β-actin. The horizontal line indicates arithmetic mean value. Non-parametric Kruskal-Wallis with
Dunn’ post-test was used to analyze the statistical significance of the differences between the groups (* = p <0.05). B. Representative
immunohistochemical staining used in the tissue array analysis. P63 (blue) and Bag5 (brown) staining are shown. Bening (Be) and cancer (Ca)
tissue is indicated. C. Tissue microarray containing tissue cores of 91 cancer cases. The horizontal line indicates arithmetic mean value. (**p <
0.001). D. Western blot analysis of Bag5 protein expression in prostate cancer patients comparing cancer (C) and surrounding benign tissue (B).
β-actin was used as equal loading control. E. Western blot analysis of Bag5 protein expression in an in vitro prostate tumor progression model
using RWPE-1 (benign), WPE-NB14 (primary tumor) and WPE-NB26 (metastatic tumor) cells. β-actin was used as equal loading control. F. Western
blot analysis of Bag5 protein expression in prostate cell lines. Equal loading control was checked with β-actin.
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but it also modified its subcellular localization. In resting
conditions Bag5 showed a diffuse staining in the cyto-
plasm. However when cells were treated for 12 hours
with TG, Bag5 staining became perinuclear and a strong
co-localization with the ER was observed as determined
by the use of the ER tracker (Figure 2D). Quantification
of the co-localization in three fields of three independent
experiments making use of the software IMARIS ColocW
showed that indeed Bag5 was significantly enriched in
the ER after stress induction (Figure 2E). This result was
confirmed by a fractionation experiment in which it
could be shown that already after 8 h of TG treatment
the ratio of Bag5 in the ER compared to the cytoplasm
was substantially increased (Figure 2F). A similar in-
crease in the distribution of GRP78/BiP in the ER was
also observed (Figure 2F).
Bag5 interacts with GRP78/BiP
Since Bag5 localizes at least partially in the endoplasmic
reticulum, we wanted to investigate whether as co-
chaperone was able to interact with the major chap-
erones in this organelle. GST-pull down assay was
therefore carried out with GST-fused Bag5 and lysates of
22Rv.1 prostate cancer cells. Western blot analysis with
specific antibodies showed that Bag5 interacted with
GRP78/BiP but it did not bind other ER chaperones
such as protein disulfide isomerase (PDI) or GRP94(Figure 3A). The interaction of Bag5 and GRP78/BiP
was confirmed in a co-immunoprecipitation assay in
HEK293 cell transfected with HA-Bag5 (Figure 3B).
As Bag5 is made up of five BAG domains, it was
necessary to determine whether all the five domains
bind equally to GRP78/BiP. A GST-pull down assay was
therefore performed with 22Rv.1 cell lysate and GST-
fused carboxy- and amino-terminal deletion mutants of
Bag5 that sequentially deleted one BAG domain at a
time (Figure 3C and E). Deletion of the fifth BAG-
domain abrogated binding of GRP78/BiP to the full
length Bag5 protein while sequential deletion of the N-
terminal sequences up to the fifth BAG domain mod-
ulated but did not abolish binding to GRP78/BiP
(Figures 3C and D). This confirmed that the fifth BAG
domain is responsible for binding to GRP78/BiP.
Bag5 modulates GRP78/BiP activity
To determine the domains of GRP78/BiP to which Bag5
binds, GST-pull down studies were carried out with
GST-ATPase and GST-substrate binding domains of
GRP78/BiP along with extracts from HEK293 cells pre-
viously transfected with an HA-Bag5 construct. These
studies show that Bag5 interact with the ATPase domain
of GRP78 but not the SBD (Figure 4B). Binding of Bag5
to the ATPase binding domain of GRP78/BiP suggests
that Bag5 may affect the ATPase activity of GRP78/BiP.
In an in vitro ATPase hydrolysis assay we could show
Figure 2 Bag5 is stress-induced and accumulates in the endoplasmic reticulum. Bag5 gene expression is induced upon stress. A. Real time
PCR analysis of Bag5 gene in 22Rv.1 cells upon treatment with thapsigargin (TG) or tunicamycin (TN) for the indicated time points. Gene
expression values were normalized to Rib36. Bar charts indicate the mean value of three independent experiments ± SD. (* p < 0.05) B. Real time
PCR analysis of GRP78 gene in 22Rv.1 cells upon treatment with thapsigargin (TG) or tunicamycin (TN) for 12 h. Gene expression values were
normalized to Rib36. Bar charts indicate the mean value of three independent experiments ± SD. (* p < 0.05; ** p < 0.01). C. Bag5 protein
expression is induced upon stress. Western blot analysis of 22Rv.1 cell extracts after thapsigargin or tunicamycin treatment for the indicated time
points. β-actin was detected as loading control. D. Bag5 accumulates into the ER upon stress. D. Bag5 associates to the ER upon stress. Confocal
microscopic analysis of 22Rv.1 cells-paraformaldehyde-fixed and stained with an anti-Bag5 antibody (green channel) or the ER-tracker
(red channel) after 12 hours thapsigargin treatment. All images (40X) were acquired with a Leica TCS SPE confocal microscope
(Leica Microsystems). The scale bar indicates 25 μm. E. Quantification of the percentage of co-localization performed with the software Imaris
CoLoc. Bar charts indicate the average of three fields of three independent experiments ± SD (* p < 0.01). F. ER extraction from 22Rv.1 cell lysates
treated with TG for 8 h. Western blot analysis was performed with a Bag5 or a GRP78 specific antibody. Anti-α-tubulin was used for ER fractions
quality control (C: cytoplasm; ER: endoplasmic reticulum).
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of GRP78/BiP but not Bag5 mutant lacking the fifth Bag
domain (Bag5Δ 5) (Figure 4C) although both proteins
employed in the assay were expressed at equal levels
(Figure 4D).
Bag5 expression levels modulate the unfolded protein
response
Stressful conditions such as nutrient starvation, hypoxia
or changes in pH to protect cells and promote cellsurvival activate a signaling pathway known as the UPR
[28]. However, when stressful conditions are prolonged,
the UPR induces apoptosis by shutting down protein
synthesis [29]. Since the UPR is regulated by GRP78/BiP
[30] and Bag5 binds this protein, we investigated if
alteration of the level of Bag5 would affect the UPR. We
overexpressed Bag5 by stable transfection in 22Rv.1 cell
with an HA-Bag5 or an empty vector as control and in-
duced the UPR by exposure of these cells to thapsigargin
for 6 and 12 h.
Figure 3 Bag5 interacts with GRP78/BiP. A. Bag5 interacts with GRP78/BiP but not with GRP94 and PDI. GST-pull down assay performed
incubating 10 μg of GST-Bag5 and 250 μg of 22Rv.1 cell lysate. Equal recombinant protein employed in the assay was checked by staining the
membrane with coomassie. 5% of the lysate was loaded as input. B. Bag5 and GRP78 interact in vivo. Co-immunoprecipitation assay performed in
HEK293 cells transfected with HA-Bag5. GRP78/BiP was immunoprecipitated with an anti-GRP78 specific antibody and IgG was used as negative
control. Western blot analysis was performed with an anti-HA and anti-GRP78 antibody. C-F. The fifth Bag domain of Bag5 mediates the
interaction with GRP78/BiP. C and E. Diagrammatic representation of Bag5 and the deletion mutants used for the GST-pull down assay. D and F.
GST-pull down assay performed incubating 10 μg of GST-fused protein and 500 μg of 22Rv.1 cell lysate. An anti-GRP78 antibody was used for
western blot analysis. The membrane was stained with coomassie for equal protein amount employed in the experiment.
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kinase/endonuclease IRE1α, the transcription factor
ATF6 and the kinase PERK. While the first two branches
promote cell survival, the third is responsible for apop-
tosis induction [31,32]. Overexpression of Bag5 resulted
in decreased cleavage of the transcription factor ATF6
(cATF6) while it produced an increase in the basal levels
of IRE1α phosphorylation (Figure 5A). In addition Bag5overexpression reduced the expression of the kinase
PERK resulting in a reduced phosphorylation of the
PERK downstream target eIF2α and of the transcription
factor ATF4 (Figure 5A). These observations correlated
with a Bag5-mediated decrease in expression of the tran-
scription factor CHOP/GADD153 since it is regulated
by ATF4 (Figure 5B). In addition we could also observe
increased expression of the anti-apoptotic factor Bcl-2, a
Figure 4 Bag5 functions as co-chaperone of GRP78/BiP.
A. Diagrammatic representation of the molecular chaperone GRP78/
BiP and its domains. Numbers indicate the amino acid position.
B. Bag5 binds the ATPase domain of GRP78. GST-pull down assay
was performed incubating 10 μg of GST-fused protein with 500 μg
of HEK-293 cells transfeced with HA-Bag5. A specific anti-HA
antibody was used in western blot analysis to detect the binding.
Equal recombinant protein employed in the assay was checked by
coomassie staining. C. Bag5 enhances GRP78/BiP ATP hydrolysis.
ATPase assay with purified GRP78 in absence or presence of Bag5
(dashed line) or Bag5Δ 5 (dotted line). Results are expressed as the
average of three independent experiments ± SD (* p < 0.05)
D. Coomassie staining of the proteins employed in the ATPase assay.
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http://www.biomedcentral.com/1471-2407/13/96gene suppressed by CHOP (Figure 5A). As CHOP triggers
apoptosis by inducing Bax and suppressing Bcl-2 gene ex-
pression [33], we also analyzed the expression of these two
genes. Bag5 overexpression resulted not only in a
decreased CHOP/GADD153 (Figure 5B) but also in a de-
creased Bax and an increased Bcl-2 expression (Figures 5C
and D) gene expression. Furthermore since an increase
in the phosphorylation of the kinase/endonuclease IRE1α
was observed upon Bag5 overexpression, we analyzed the
splicing of the target Xbp1 by RT-PCR (Xbp1s). As shown
in Figure 5E, Xbp1 splicing was increased in Bag5 clones
compared to the vector control.
To confirm these results, Bag5 expression was reduced
in 22Rv.1 cells in a siRNA knock down experiment and
the cells were treated for 6 and 12 h with thapsigargin (TG)
to activate the UPR. Consistent with the overexpression
results, a knock down of Bag5 expression is expected to
produce the reverse results. Indeed the downregulation
of Bag5 expression resulted in an increased eIF2α but
a decreased IRE1α phosphorylation (Figure 5F). Taken
together these results indicate that Bag5 induces the IRE1αpro-survival branch while it inhibits the PERK-eIF2α-ATF4
pro-apoptotic axis.
Bag5 overexpression increases stress tolerance in
prostate cancer cells
To determine if the anti-apoptotic activity of Bag5 is spe-
cific to thapsigargin, a clonogenic assay was performed with
22Rv.1 cells transfected with a Bag5 or an empty expression
vector and treated with several stress-inducing compounds
such as tunicamycin, (-)-epigallocatechingallate (EGCG),
feneretinide, taxol or glucose- or serum-starved. Over-
expression of Bag5 in all the cases analyzed increased sur-
vival of the cells compared to the vector control cells
(Figure 6A). In addition we could show that stress-induced
apoptosis assayed by caspase-3 cleavage in the same culture
conditions was decreased in the Bag5 transfected cells
compared to the control cells. In the case of thapsigargin
treatment we could show the converse experiment in that
siRNA knock down of Bag5 induced apoptosis measured
by PARP cleavage (Figure 6C). This result was even more
convincing for the metastatic cell line PC3 (Figure 6C),
where Bag5 levels are higher compared to the 22Rv.1
(Figure 1F). These studies demonstrate that Bag5 protects
against stress-induced apoptosis.
Discussion
In this work we showed that Bag5 interacts with the mo-
lecular chaperone GRP78/BiP demonstrating that in
addition to the function of Bag proteins as interaction
partners of Hsp70/Hsc70, a member of this family (Bag5)
additionally interacts with the ER-resident chaperone
GRP78/BiP. This expands the network of interaction part-
ners of the Bag family of co-chaperones. In addition we
showed for the first time at the RNA and protein levels that
Bag5 is overexpressed in prostate cancer and that it plays a
role as a pro-survival factor in UPR-induced apoptosis.
Bag5 is a co-chaperone of GRP78/BiP and promotes
cancer cell survival
Bag proteins have been described to interact with the
molecular chaperone Hsp/Hsc70 [2] but recently it is
reported that Bag-1 interacts with the ER chaperone
GRP78/BiP [34] suggesting that other Bag proteins may
share this property. In this study we could show that
Bag5 also interacts with GRP78/BiP confirming that the
Bag proteins may be more versatile in their interactions
with molecular chaperones. However Bag5 does not
interact with all ER-resident chaperones, it does not
interact with the protein disulfide isomerase PDI or the
Hsp90 homolog GRP94 showing selectivity in its inter-
action partners. The observation that Bag5 interacts with
GRP78 and stimulates its ATPase activity expands the
range of action of the Bag proteins in other cellular events
such as ER-mediated stress response and the UPR.
Figure 5 Bag5 overexpression modulates the unfolded protein response. A. 22Rv.1 stably overexpressing Bag5 showed increased IRE1/Xbp1
axis activation. Western blot analysis of 22Rv.1 cells stably transfected with pcDNA3.1-HA-Bag5 or the empty vector as control. After treatment
with TG for the indicated time points, cells were lysed and subjected to western blot analysis using the indicated antibody. As equal loading
control an anti-β-actin antibody was used. B - E. Real time-PCR analysis of 22Rv.1 cells stably expressing the empty vector control (open bars) or
HA-Bag5 (filled bars) treated with TG for the indicated time points. Gene expression analysis was performed for CHOP (B), Bcl-2 (C), Bax (D) and
the spliced form of Xbp1, Xbp1s (E). Values were normalized to Rib36. Bar charts indicate the mean of at least three independent experiments ±
SD (*p <0.05; ** p < 0.01). F. Western blot analysis of 22Rv.1 cells transfected with siRNA targeting GFP or Bag5 and treated with TG for the
indicated time points. Anti-α-tubulin was used as equal loading control.
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http://www.biomedcentral.com/1471-2407/13/96From the analysis of the effect of Bag5 in the UPR, we
could show that it preferentially stimulates IRE1α while
it suppresses PERK/eIF2α pathways resulting in growth
advantage for the cells. The action of Bag5 in regulating
events in the ER is consistent with its increased associ-
ation to this cellular compartment following thapsigargin
treatment even if the mechanism by which it is recruited
to the ER is not clear and needs further investigation. In-
triguingly we could also observe that ectopic expression
of Bag5 resulted already in untreated cells in increased
Bcl-2 and decreased Bax expression independent from
stress induction. It is possible therefore that Bag5 could
contribute to cell survival both by interacting with
GRP78 enhancing its enzymatic activity and by modu-
lating Bcl-2/Bax ratio and that these two events could be
independent from each other.
Bag5: a new tumor marker?
RNA and protein expression studies presented in this
work show that the expression of Bag5 is increased in ma-
lignant compared to benign prostate tissue. Since other
Bag family members are overexpressed in several types ofcancers in addition to prostate cancer [35-37], such as
breast [38,39], colon [40] and pancreatic [41,42] cancers,
it is likely that increased Bag5 expression would be found
in other type of tumors as well. If this is the case, it would
be worth investigating the use of Bag5 as a novel tumor
biomarker.
From the results of this work that Bag5 is a stress-
inducible gene and it is anti-apoptotic, we would expect a
tumor with high expression of Bag5 to be more aggressive
and less responsive to stress-inducing chemotherapeutic
agents. This hypothesis is supported by our observation
that up- or downregulation of Bag5 levels modifies the
ability of prostate cancer cells to respond to stress. This
agrees with finds that Bag5 gene expression is increased
in rat livers upon exposure to epatotoxants [43] and that
it is induced in MCF7 breast cancer cells [44] and ovarian
cancer spheroids [45] upon taxol treatment.
Conclusions
These finding together with the work described in this
communication identify Bag5 as a gene whose expression
is regulated by chemotherapeutic drugs and an anti-
Figure 6 Bag5 increases prostate cancer cell chemoresistance. Modulation of Bag5 levels influences prostate cancer cell response to
chemotherapy. A and B. Colony forming assay (A) and caspase-3 cleavage analysis (B) of 22Rv.1 cells stably expressing the empty vector control
(open bars) or HA-Bag5 (filled bars). Bar charts represent the average of three independent experiments ± SD. * p < 0.05. (TG: thapsigargin, 75 nM;
TN: tunicamycin, 10 μg/ml; EGCG: (-)-epigallocatechingallate, 10 μM; Fen: fenretinide, 20 μM; GS: glucose starvation; SS: serum starvation;
Tax: taxol, 10 nM). * p < 0.05; ** p < 0.01. C. Western blot analysis of 22Rv.1 and PC3 cells transfected with siRNA targeting Bag5 or GFP as control
and treated with 300 nM TG for 24 hours. Anti-β-actin antibody was used as equal loading control.
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http://www.biomedcentral.com/1471-2407/13/96apoptotic gene. In addition we showed that Bag5 interacts
with the molecular chaperone GRP78/BiP, often found
overexpressed in chemoresistant tumors (reviewed in
[46]). Downregulating Bag5 levels and/or interfering with
Bag5-GRP78/BiP interaction could therefore represent a
novel therapeutic approach to overcame chemoresistance
and to treat late stage tumors.
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Additional file 1: Figure S1. Bag5 is stress-induced in PC3 cell lines.
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